Form 4: Tempest Therapeutics Director Granted Stock Options

Tempest Therapeutics director Christine A. Pellizzari was granted 1,230 stock options with an exercise price of $2.94.

Summary

• Christine A. Pellizzari, a Director of Tempest Therapeutics, Inc. (TPST), was granted 1,230 stock options.
• The options have an exercise price of $2.94 per share.
• The grant date for these options was January 27, 2026.
• The options expire on January 26, 2036.
• The shares underlying the option will vest in full on the earlier of January 27, 2027, or the day of the Issuer's 2026 annual stockholder meeting, contingent on continuous service.

Sentiment

Score: 6

Explanation: The filing reports a routine stock option grant to a director, which is a neutral to slightly positive event as it aligns management incentives with shareholder interests. It does not contain significant news that would drastically alter sentiment.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date, providing a long window for potential value realization.

Negatives

• No immediate negatives are apparent from a routine stock option grant.

Risks

• The value of the stock options is subject to the future market price of Tempest Therapeutics, Inc. common stock, which may decline.
• Vesting is contingent on continuous service, meaning the director must remain with the company to realize the full benefit.

Future Outlook

The stock options are designed to incentivize future performance, with vesting contingent on the director's continuous service through January 27, 2027, or the 2026 annual stockholder meeting.

Industry Context

Routine equity grants to directors are a standard practice across the biotechnology and pharmaceutical industries to attract and retain talent and align interests with shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of non-cash compensation in publicly traded companies, particularly in the biotech sector, similar to practices at companies like Moderna or Pfizer for their non-executive directors.
• The vesting schedule, tied to either a specific date or the annual meeting, is a standard mechanism to ensure continued service and alignment.
• The 10-year expiration period for options is also a typical duration for such grants.

Related Party Transactions

• The grant of stock options to Christine A. Pellizzari, a Director of Tempest Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation. Potential dilution from option exercise is minimal given the small number of shares.
• Employees: No direct impact on general employees is indicated.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• The stock options will vest in full on the earlier of January 27, 2027, or the day of the Issuer's 2026 annual stockholder meeting, subject to continuous service.

Key Dates

Keywords

Tempest Therapeutics, TPST, stock options, director compensation, SEC Form 4, insider transaction, equity grant, Christine A. Pellizzari